Insilico Medicine collaborates with the Indiana Biosciences Research Institute to apply novel artificial intelligence-powered approaches to multi-omics data analysis and discovery of potential therapeutic targets
June 9, 2021 - Insilico Medicine, a global leader in deep learning for drug discovery and development, is pleased to announce that it has entered into a research collaboration with the Indiana Biosciences Research Institute (IBRI). The IBRI will use Insilico's generative machine learning technology and proprietary PandaOmics Drug Discovery Platform to identify novel therapeutic targets implicated in a variety of diseases, OMICS data analysis, and systems biology research.
"PandaOmics is a comprehensive AI-powered platform that will help improve our drug discovery processes and accelerate translational research," said Dr. Daniel Robertson, vice president of digital technology at the IBRI. "This platform will enable us to quickly access, analyze, visualize, and interpret externally-available data effectively to drive our research efforts."
Target discovery is the most risky yet rewarding area in healthcare. It is easy to pick the target for a specific disease, but the wrong choice will result in a Phase II clinical trial failure many years and spending of hundreds of millions of dollars later. Target discovery is usually performed in academic, research and clinical institutions, where the world's most competent researchers formulate disease hypotheses and perform the exploratory experiments. AI systems that incorporate and accelerate the many target discovery philosophies that worked in the past in addition to the novel approaches are likely to significantly increase the chances of successful target discovery.
"Since 2014 we have been developing AI, advanced bioinformatics, and business intelligence tools to identify novel targets for a variety of diseases. Many of these tools and target discovery philosophies are now available in PandaOmics, and we are very happy that the leading research institutions specializing in novel drug discovery are using PandaOmics to augment their discovery capabilities," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.
PandaOmics integrates more than 60 different engines and approaches to target discovery. It provides biologically interpretable insights coupled with business intelligence with multiple experimentally validated case studies. PandaOmics aims to be the go-to platform for all biologists and clinicians, working with various OMICS datasets.
###
About Insilico Medicine:
Since 2014 Insilico Medicine has been focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 130 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.
About Indiana Biosciences Research Institute:
The Indiana Biosciences Research Institute (IBRI) is a nonprofit discovery science and applied research institute currently targeting diabetes, metabolic disease, poor nutrition and related health data science. Inspired by Indiana's leading life sciences companies, research universities and philanthropic community, the IBRI is building a world-class organization of researchers, innovators and entrepreneurs to catalyze scientific discovery and its applications, resulting in improved health outcomes for Indiana patients and beyond. For more information about the IBRI, visit https:/
For further information, images or interviews, please contact: polly.firs@insilico.com
No comments:
Post a Comment